COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT

摘要

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGFlR inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IGFlR inhibitor compound of Formula I combination with a pharmaceutically acceptable carrier. The IGFlR inhibitor is represented by Formula I. wherein X₁ X₂, X₃, X₄, X₅, X₆, X₇, R¹, and Q¹ are defined herein.